Investor News / RNS

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of treatment regimens for cancer and other therapeutic drugs for the biopharma industry, is pleased to announce that it is attending the #BIOEurope conference in person in Leipzig, Germany on 24-26 October 2022.   BIOEurope is one of the world’s premier biotech partnering conferences and is expected to host over 4,000 executives from over...

Physiomics plc (AIM: PYC), the consultancy company offering expertise in mathematical modelling and simulation to enable smarter decision making in drug development for the biopharma industry, is pleased to announce that it has signed an agreement to work with Cancer Research UK.   Physiomics will use its PKPD modelling capabilities to support the Cancer Research UK sponsored early phase clinical development of ALETA-001, a CAR-T cell engager...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a third contract by existing client, Numab Therapeutics (“Numab”).  Physiomics will use its PKPD modelling capabilities to support the translation of pre-clinical to clinical data with a focus on dose selection.  The project is expected to...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce its results for the full year ended 30 June 2022 as well as the date of its 2022 Annual General Meeting. Click here to read in full....

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it will publish its results for the full year ending 30 June 2022 on Thursday, 29 September 2022.   Enquiries:   Physiomics plc                                                   Dr Jim Millen, CEO +44 (0)1865 784 980    Hybridan LLP (broker) Claire Louise Noyce +44 (0) 203 764 2341   Strand Hanson Ltd (NOMAD) James Dance...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Mr Shalabh Kumar has joined the Company's board as an Independent Non-Executive Director with immediate effect. Click here to read in full....

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, yesterday made a Trading update presentation.   The slide deck used in the presentation can be accessed on the Company’s website using the following link:   https://www.physiomics.co.uk/wp-content/uploads/2022/07/Trading-update_13-07-2022.pdf   A recording of the presentation can be viewed by view by using the below link:   https://www.youtube.com/embed/_-jUnKpcbpo...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, today announces that its total income and profit after tax for the financial year ended 30 June 2022 is likely to be in-line with market expectations.   During the year the Company made planned investments in the hiring of three new staff members (two technical and...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Dr Cristian Gradinaru has joined its technical team as a Senior PKPD Modeller.   Cristian holds a PhD from the Technical University of Copenhagen, Denmark in Stochastic Modelling of Biological Systems, and an MSc from Stanford University, USA in Biophysics. He...

The Company considers that the award of options linked to the Company’s performance is critical to the incentivisation of its employees and to ensure that there is alignment between management and shareholders.   To this end, the Company today confirms that it has agreed to issue 850,000 share options (the “Options”) over ordinary shares of 0.4p each in the Company (“Ordinary Shares”) to its non-director employees, under...